Abstract: Compositions and methods related to stromal antigen 2 (STAG2) and its role in diverse human cancers, including nucleic acids, polypeptides, vectors, cells and cell lines.

Abstract: Human somatic cells obtained from individuals with a genetic heart condition are reprogrammed to become induced pluripotent stem cells (iPS cells), and differentiated into cardiomyocytes for use in analysis, screening programs, and the like.

Abstract: A concentration measurement method for measuring the concentration of a target molecule, capable of carrying out a quantitative measurement of the concentration by use of a chip. A relationship between concentration of a target molecule of a calibration liquid, found with respect to a calibration chip identical in performance to the measurement chip and a measured quantity of light is found when the probe molecule and the target molecule undergo bonding reaction in a condition where the specific probe molecule and the target molecule undergo bonding reaction using the calibration chip.

Abstract: This invention relates to methods to detect the presence of cancer infiltration of the Central Nervous System (CNS) based on the detection of soluble proteins, preferably, in cerebrospinal fluid samples and vitreous fluid. The invention also relates to kits to perform the methods of the invention.

Abstract: Provided is a method for determining whether an individual is at risk for, or has a metabolic muscle disease. The method involves testing a biological sample obtained or derived from an indivdival for the presence or absence of at least one mutation from a plurality of mutations in genes related to muscle metabolism and identifying the individual as having or at risk for developing a metabolic muscle disease based on the presence or absence of the mutation.

Abstract: The present invention pertains to materials and methods for diagnosing and/or determining the prognosis and likelihood of developing asthma. In one embodiment, methods of the invention comprise the use of single nucleotide polymorphic markers of asthma. Markers of the invention are present in the atria natriuretic peptide (NPPA) gene, and serve as a marker for genetic susceptibility of a person or animal in developing asthma.

Abstract: A method of stratifying a subject having adolescent idiopathic scoliosis (AIS) comprising: providing a cell sample isolated from the subject; detecting Paired-like homeodomain transcription factor 1 (Pitx1) expression in the cell sample; whereby the results of the detecting step enables the stratification of the subject having AIS as belonging to an AIS subclass.

Abstract: Provided are a device, whereby cells, a bacterium or a virus can be quantified in a single unit, an assay system and an assay method. A subject to be assayed such as cells, a bacterium or a virus, which are present on a sensor, can be quantified by using a sensor equipped with multiple electrodes, said electrodes being similar in size to the subject to be assayed, detecting, concerning each electrode, the presence or absence of the subject in the vicinity of the electrode, and adding up the electrodes in which the subject is detected.

Abstract: A method for determining pulmonary fibrosis subtype and/or prognosis in a subject having pulmonary fibrosis comprising: a. determining an expression profile by measuring the gene expression levels of a plurality of genes selected from genes listed in Table 1, 2, 3, 4 7, 8, 9, and/or 10, in a sample from the subject; and b. classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts decreased risk of post lung transplant primary graft dysfunction, and wherein a poor prognosis predicts an increased risk of post lung transplant primary graft dysfunction.

Abstract: The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as colorectal cancer, and using the profile in the diagnosis and/or prognosis of a patient for a condition, such as colorectal cancer and colorectal cancer recurrence or response to therapy.

Abstract: Substrates and devices for culturing cells are disclosed, along with methods of using the same. The substrates and devices include top surfaces with one or more divots disposed therein. Each divot is defined by an opening in the top surface, a rounded bottom surface spaced from the opening, and an interior side-wall surface extending between the rounded bottom surface and the opening. The top surface of the substrates and devices are optionally walled to form wells containing one or more divots. The substrates and devices may be used for reaggregating cells, for example, to form small islet cell clusters and for high throughput testing methodologies.

Abstract: The invention relates to a nucleic acid comprising the following contiguous elements arranged in the 5 prime to 3 prime direction; a promoter; a selectable marker; a cloning site for receipt of a nucleic acid segment, said segment comprising a candidate miRNA target sequence; and a poly adenylation signal, said elements arranged such that a transcript directed by said promoter comprises said selectable marker, said candidate miRNA target sequence, and said poly adenylation signal in that order. Suitably the miRNA test sequence is or is derived from a 3?UTR. The invention also relates to methods for making and screening libraries.

Abstract: The invention generally relates to methods and apparatuses for optimizing conditions for optical mapping. In certain embodiments, methods of the invention involve providing a substrate including a gradient of silanes in a first direction, introducing to the substrate, a gradient of enzyme activity in a second direction, contacting a plurality of enzymes and a plurality of nucleic acids to the substrate, and analyzing enzymatic activity and interaction of the nucleic acids with the substrate, thereby determining the optimal conditions for optical mapping of the nucleic acid.

Abstract: Provided are a method for measuring histone methyltransferase activity, a method for screening for compounds that inhibit histone methyltransferase activity, a reagent kit for measuring histone methyltransferase activity, and a kit for screening for compounds that inhibit histone methyltransferase activity. A substrate compound represented by general formula (I): R1—X—K—R2 (I), or a salt thereof, wherein R1 represents a hydrogen atom or a protecting group for an amino terminus; X represents a peptide consisting of 0 or 1 or more amino acid residues; K represents a lysine residue; and R2 represents a dye label linked via an amide bond to the carbonyl terminus of a lysine residue, wherein the cleavage of the amide bond by peptidase changes the fluorescence property or chromogenic property of the dye label, and the methylation of the ? amino group of the lysine residue by the histone methyltransferase decreases susceptibility to peptidase, is used.

Abstract: Systems, methods, libraries, kits, and computer software tools are provided for designing and producing engineered cells. Such engineered cells can be used for cell state quantification, such as genome, transcriptome and/or proteome quantification. In one aspect, an engineered cell having a plurality of artificially designed oligonucleotides introduced into the genome of the cell is provided. The oligonucleotides are each located in proximity of a gene of interest encoding a protein of interest, and are different from one another. The oligonucleotides can each encode a unique peptide tag for each protein of interest, wherein each peptide tag has a unique quantitatively measurable value such as mass-to-charge ratio which can be quantified by a mass spectrometer. The engineered cell is capable of expressing a plurality of proteins of interest each fused to its corresponding unique peptide tag, wherein each peptide tag is capable of being released therefrom.

Abstract: Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.

Abstract: Methods are provided for adding a terminal sequence tag to nucleic acid molecules for use in RNA or DNA amplification. The tag introduced may be used as a primer binding site for subsequent amplification of the DNA molecule and/or sequencing of the DNA molecule and therefore provides means for identification and cloning of the 5?-end or the complete sequence of mRNAs.

Abstract: The invention relates to a nucleic acid comprising the following contiguous elements arranged in the 5 prime to 3 prime direction; a promoter; a selectable marker; a cloning site for receipt of a nucleic acid segment, said segment comprising a candidate miRNA target sequence; and a poly adenylation signal, said elements arranged such that a transcript directed by said promoter comprises said selectable marker, said candidate miRNA target sequence, and said poly adenylation signal in that order. Suitably the miRNA test sequence is or is derived from a 3?UTR. The invention also relates to methods for making and screening libraries.

Abstract: A gas generating system for use in stimulation or in deliquification/dewatering includes a foam generating agent, a foam enhancing agent and a gas generating additive. The foam generating agent is absorbed or adsorbed on a first plurality of substrates and the foam boosting agent is absorbed or adsorbed on a second plurality of substrates. The gas generating additive preferably includes an acidic component contained within a releasing mechanism container and a carbonate or bicarbonate contained within a releasing mechanism container. The use of encapsulated substrate permits the staged and targeted delivery of treatment chemicals in fractures extending from the wellbore or in the wellbore itself.

Abstract: Biocide compositions comprising biocide, surfactant, and solubilizing agent. The preferred biocide is parachlorometaxylenol. The biocide composition is useful in oil and gas drilling operations, such as hydraulic fracturing, as well as treating aqueous slurries in ore mining operations. The biocide compositions are effective in controlling microorganisms even in the presence of high salt content water and at high temperatures.

Abstract: The invention relates to a method for producing expanded glass granules. To this end, starting materials are provided, comprising 80% to 95% glass and 5% to 20% sodium silicate hydrate having a water of crystallization content between 1 and 2 wt %, in relation to the solids content. After the glass is ground, the starting materials are mixed, the ground starting materials are granulated into raw granules, and the raw granules are mixed with a release agent, the mixture comprising the raw granules and the release agent is heated to a processing temperature. In a first partial step, the pores on the surfaces of the particles of the raw granules are closed, and in a second partial step, the water of crystallization is dissolved from the sodium silicate hydrate and caused to thermally expand, whereby the particles of the raw granules expand and form the expanded glass granules.

Abstract: A composite particle comprises a core, a shielding layer deposited on the core, and further comprising an interlayer region formed at an interface of the shielding layer and the core, the interlayer region having a reactivity less than that of the core, and the shielding layer having a reactivity less than that of the interlayer region, a metallic layer not identical to the shielding layer and deposited on the shielding layer, the metallic layer having a reactivity less than that of the core, and optionally, an adhesion metal layer deposited on the metallic layer.

Abstract: A process and corresponding apparatus and system for use in preparing soaps from fatty acid containing oil compositions, and in turn, for preparing greases by the use of such soaps in combination with one or more base oils.

Abstract: A lubricating grease composition for extra heavy duty extreme pressure applications comprises a major amount of a synthetic base oil a lithium complex thickener, at least one extreme pressure agent; and at least 5 wt. % of molybdenum disulfide, based on a total weight of the lubricating grease composition.

Abstract: The lubricant for a sump-lubricated, compression-ignited engine may contain an amount of a C12-C24 carboxylic acid-based fuel additive or component obtained by migration from the fuel. Good lubricant performance is obtained by including in the lubricant a boron-containing additive in an amount to provide about 2 to about 500 ppm B to the lubricant, provided that the total sulfated ash level is less than 0.8 weight percent.

Abstract: A lubricating oil composition containing a bis-type alkenyl-substituted succinimide which is prepared by reaction of succinic anhydride substituted with 2-alkenyl group having a branched structure in ?-position with alkylenepolyamine or a compound derived from the bis-type alkenyl-substituted succinimide by post-treatment in combination with a mixture of an overbased sulfonate having a C20-C24 alkyl group and an overbased salicylate having a C14-C18 alkyl group shows a high friction coefficient within a wide sliding velocity range and keeps its high anti-shudder performance for a long period of time.

Abstract: Provided is a turbine oil formulation comprised of a base oil selected from the group consisting of Group II, III and IV base oils and mixtures thereof, and an ester component comprised of at least one diester or triester species having ester links on adjacent carbons. The formulation exhibits less than 6 mg of sludge/100 ml of turbine oil, and is imminently suitable for use as a turbine oil.

Abstract: Provided is a lubricant oil composition for an internal combustion engine which is characterized by including a base oil having a viscosity index of 125 or higher and a Noack evaporation amount (250° C.×1 h) of 15% by mass or less, and, based on a total amount of the composition, from 0.1 to 10% by mass of (A) a C2 to C20 olefin polymer having a mass average molecular weight of 500 or more and 10,000 or less and/or (B) a polymeric compound having a mass average molecular weight of 10,000 or more and less than 100,000, wherein a content of (C) a polymeric compound having a mass average molecular weight of 100,000 or more is less than 1.0% by mass. The lubricant oil composition can, despite of its low viscosity, reduce noise during running, prevent fatigue damage such as gear pitting, reduce the consumption of the oil, and provide excellent fuel saving performance.

Abstract: Provided is a process for preparing a turbine oil formulation comprised of a base oil selected from the group consisting of Group II, III and IV base oils and mixtures thereof, and an ester component comprised of at least one diester or triester species having ester links on adjacent carbons. The formulation exhibits less than 6 mg of sludge/100 ml of turbine oil and is imminently suitable for use as a turbine oil.

Abstract: The invention relates to a multiphase liquid detergent composition comprising at least two visually distinct liquid phases and a surfactant. At least one of the visually distinct phases has a high shear viscosity between about 100 cps and 15,000 cps at 20° C., a medium shear viscosity between about 5,000 cps and about 60,000 at 20° C., and a low shear viscosity between about 10,000 cps and 500,000 cps at 20° C. The present invention further relates to methods of cleaning dishware using such multiphase liquid detergent compositions.

Abstract: The invention relates to a multiphase liquid detergent composition comprising at least one cleaning phase and at least one benefit phase, a surfactant, and a crystalline structurant. The crystalline structurant being substantially present in a non-lamellar phase. The invention also relates to a multiphase liquid detergent composition comprising at least two visually distinct liquid phases, a surfactant, and at least two incompatible or reactive materials. The first incompatible or reactive material is distributed in a first visually distinct phase and a second incompatible or reactive material is distributed in a second visually distinct phase. The present invention further relates to methods of cleaning dishware using such multiphase liquid detergent compositions.

Abstract: This disclosure relates to detergent compositions containing tiron, a ligand capable of binding iron, an iron-displacing species, and iron. Methods for altering the color in a tiron-containing detergent composition are also disclosed.

Abstract: The present invention provides a mutant alkaline cellulase having enhanced anti-redeposition ability.

Abstract: A liquid detergent composition has a thickening system which comprises; (a) a carboxylic acid/carboxylate polymer, and (b) a polymer comprising an ammonium group.

Abstract: A surfactant concentrate is provided that includes (i) from 35% to 90% by weight a C8-C22 acyl amido surfactant of structure (I) wherein R is a C7-C22 saturated or unsaturated alkyl radical; R2 is hydrogen, CH2COOX or a C1-C5 alkyl radical; R3 is hydrogen; R4 is selected from the group consisting of (CH2)mCO2X, (CH2)mSO3X, CH2NR2(CH2)mOH and glucosyl radicals; R5 is selected from the group consisting of hydrogen, hydroxyphenyl, C1-C6 hydroxyalkyl, C1-C10 alkyl, benzyl, hydroxybenzyl, alkylcarbamido, thioalkyl, and carboxylic radicals; X is selected from hydrogen, metal ions, amine salts and C1-C4 alkyl radicals; and m ranges from 0 to 6; and (ii) from 10 to 60% by weight of polyol; and (iii) from 1 to 20% by weight of C8-C22 fatty acids; and wherein the concentrate has a pH ranging from 9 to 13.

Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugate having a peptide linkers and more specifically to conjugates of formula (I). The invention also provides novel cytotoxic agents of formula (II), linker compounds represented by formula (III), and drug-linker compounds represented by formula (IV). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

Abstract: Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (RT), having an affinity for bone; a Bone Active Portion (RA) for interacting with and affecting bone; and a Linking Portion (RL) connecting the Bone Targeting Portion and the Bone Active Portion.

Abstract: A peptide having the following amino acid sequence: Z1-LVRYTKKVPQVSTPTL-Z2(ALB-408) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of ALB408-423; wherein Z represents number of from 0 to 10 amino acid residues.

Abstract: Azuvirin peptides are small peptide agents useful in delivering functional moieties, such as sensitizers, chemotherapeutic agents and the like to cancer cells expressing ephrin receptors. The peptides are also useful for administration to a patient suffering from a viral infection, or to an individual facing exposure to a viral infection, especially one caused by the HIV-1 retrovirus.

Abstract: Aspects of this invention include methods comprising administering a combination of a Compound (1) below, including particular en crystalline forms thereof and pharmaceutically acceptable salts thereof, with at least one further selected HCV inhibiting compound as described herein for the treatment of Hepatitis C Viral (HCV) infection The methods can be conducted administering the Compound (1) and the at least one further selected HCV inhibiting compound separately or together, including as a regimen of treatment.

Abstract: The present invention relates to a formulation containing curcuminoids exhibiting enhanced in vivo bioavailability and resultant improved efficacy, said formulation comprising curcuminoids and a gel forming, non digestive and soluble dietary polysaccharide fiber galactomannan and proteins derived from fenugreek [Trigonella Foenum graecum]. The invention also relates to a process for producing the said formulation and extracting non-digestible soluble dietary polysaccharide fiber galacomannans containing proteins from fenugreek seeds.

Abstract: It is disclosed a method of modulating a peroxisome proliferator activated receptor (PPAR) activity in a patient comprising administering to said subject an effective amount of a malleable protein matrix (MPM), uses thereof and pharmaceutical compositions comprising MPM for treating obesity related disorders and their associated metabolic impact by modulating PPAR activity.

Abstract: The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. The present invention relates a composition containing the novel polypeptides, and use of same in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease.

Abstract: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.

Abstract: Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.

Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.

Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Abstract: Methods for treating subjects having complement-mediated hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and other hemolytic anemias, the method comprising administering an effective amount of a composition that inhibits the activity of the complement alternative pathway.

Abstract: Therapeutic agents suitable for use as artificial platelets are described. The agents comprise a fibrinogen binding precursor bound to an insoluble carrier, wherein the fibrinogen binding precursor can be converted by a wound site specific agent, such as thrombin, to a fibrinogen binding component bound to the carrier. The fibrinogen binding component has increased ability to bind fibrinogen compared to the fibrinogen binding precursor. The agents may be used to treat patients with deficiencies in their own platelets, such as hereditary or acquired defects of platelet numbers (thrombocytopenia) or function (thrombasthenia).

Abstract: An object is to provide a sebum secretion inhibiting composition and a food or drink product using the same. The present inventors have conducted extensive studies and consequently found that the sebum secretion is inhibited by orally ingesting a collagen peptide, which is hydrolyzed collagen, and provide an oral sebum secretion inhibiting composition comprising a collagen hydrolysate and a food or drink product containing the composition.